| 2018 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
| LUNG CANCER |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | CLINICAL CANCER RESEARCH |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2014 | Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR | ONCOLOGIST |
| 2013 | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | LUNG CANCER |
| 2012 | Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer | ANTICANCER RESEARCH |
| 2007 | Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib | JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
| ONCOTARGET |
| 2022 | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2023 | Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies
| CANCERS |
| 2021 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study | LANCET ONCOLOGY |
| 2024 | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | THYROID |
| 2022 | Preclinical activity of NVL-655 in patient-derived models of ALK cancers, including those with lorlatinib-resistant G1202R/L1196M compound mutation | EUROPEAN JOURNAL OF CANCER |
| 2023 | Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC | CLINICAL CANCER RESEARCH |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | LUNG CANCER |
| 2019 | Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors | Cancer Chemotherapy and Pharmacology |
| 2017 | Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer | JOURNAL OF NEURO-ONCOLOGY |
| 2022 | Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial | EUROPEAN JOURNAL OF CANCER |
| 2009 | Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. | LUNG CANCER |
| 2005 | Primary idiopathic chylopericardium associated with cervicomediastinal cystic hygroma
| YONSEI MEDICAL JOURNAL |
| 2018 | Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors | NATURE BIOMEDICAL ENGINEERING |
| 2011 | Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
| EXPERIMENTAL AND THERAPEUTIC MEDICINE |
| 2019 | Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study | ANTICANCER RESEARCH |
| 2010 | Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients | ONCOLOGY |
| 2007 | Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute | JOURNAL OF SURGICAL ONCOLOGY |
| 2020 | Prognostic Implications of Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Amplification and Protein Overexpression in Hypopharyngeal and Laryngeal Squamous Cell Carcinoma
| BMC CANCER |
| 2023 | Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy
| TRANSLATIONAL LUNG CANCER RESEARCH |
| 2019 | Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models | LUNG CANCER |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2017 | Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2017 | Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
| CANCER RESEARCH AND TREATMENT |
| 2022 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | CLINICAL LUNG CANCER |
| 2022 | Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
| CLINICAL LUNG CANCER |
| 2023 | Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
| CANCER RESEARCH AND TREATMENT |
| 2019 | Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
| YONSEI MEDICAL JOURNAL |
| 2023 | Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset
| FRONTIERS IN ONCOLOGY |
| 2020 | Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
| CANCER RESEARCH AND TREATMENT |
| 2022 | Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Real-world Use of Osimertinib in Non-Small Cell Lung Cancer: ASTRIS Study Korean Subgroup Analysis | CURRENT MEDICAL RESEARCH AND OPINION |
| 2015 | Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells | LUNG CANCER |
| 2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
| 2024 | Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2013 | Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma | FUTURE ONCOLOGY |
| 2021 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2014 | Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial. | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2014 | Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements
| PLOS ONE |
| 2021 | Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? | JOURNAL OF THORACIC ONCOLOGY |
| 2017 | Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer | LUNG CANCER |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy | JOURNAL OF CLINICAL ONCOLOGY |
| 2017 | Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment | BULLETIN OF THE KOREAN CHEMICAL SOCIETY |
| 2004 | Subacute Bacterial Endocarditis Associated with Upper Endoscopy
| YONSEI MEDICAL JOURNAL |
| 2016 | Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
| ONCOTARGET |
| 2017 | Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
| JOURNAL OF CLINICAL ONCOLOGY |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
| 2023 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
| CLINICAL CANCER RESEARCH |
